Matt Dawson Launches Campaign to Drive Awareness of 'Best Kept Secret' in Cancer Treatment

Three out of Four Cancer Patients Unaware of Brachytherapy

LONDON, March 30, 2010 - Former England Rugby World Cup winner Matt Dawson today
launched the 'Because Life is for Living' campaign to raise awareness about
brachytherapy, a very precise (1) and highly effective (2) form of
radiotherapy to treat cancer.

To view the Multimedia News Release, please click:

multivu.prnewswire.com/mnr/nucletron/43245/

Photographs of Matt Dawson launching the campaign will be
available from noon (BST) on the 30th March.

According to a new cancer patient survey, 75% of patients with
cancer have never heard of brachytherapy - a state-of-the-art technology that
brings the radiation dose directly to the target cancer area,(2) avoiding
damage to healthy tissues and organs, and minimising side effects.(3) Of
those 25% who are aware, only one in four have been offered the treatment.

Professor Peter Hoskin, Consultant Clinical Oncologist from
Mount Vernon Hospital, Middlesex said, "Brachytherapy is little known among
cancer patients despite new technology having developed the practice to an
increasingly effective treatment option. With brachytherapy, many people
don't have to stay in hospital when they have brachytherapy, or if they do,
the time is much less than other options such as surgery."

"Having had close family members suffer from cancer, we
obviously wanted to find the best possible treatment available, and having
easy access to information and learning about our options was a crucial step
to helping us deal with the situation," said Matt Dawson. "That is why I
support the 'Because Life is for Living' campaign which encourages patients
and their loved ones to make informed treatment choices," he added.

The 'Because Life is for Living' campaign encourages people
with cancer and their carers to enter the new website
www.aboutbrachytherapy.com to source information that along with their
doctors can help them make informed treatment choices.

Compared to other forms of radiotherapy like external beam
(EBRT), brachytherapy can deliver the required dose of radiation over a
significantly shortened treatment time. In treating prostate cancer, for
example, normal treatment times that can take up to seven weeks with EBRT
take only one or two days with brachytherapy.(4,5) Additionally, the precise
delivery of radiation reduces the risk of unnecessary damage to surrounding
healthy tissue and organs which can help reduce side effects. Again, in
prostate cancer the risk of side effects like incontinence and erectile
dysfunction is lower than with other treatment options.(3) These factors
minimise disruption to patients and allow a faster return to everyday life.

The ICM patient survey showed that men were more likely to be
offered the treatment. Four in 10 men were aware of brachytherapy compared to
less than 1 in 10 women. Awareness among women needs to be increased because
brachytherapy can be as effective in treating female-specific indications
like breast and gynaecological cancer as it is in treating prostate cancer in
men and with the same minimised side effects.(3)

Dr Rachel Cooper, Consultant Clinical Oncologist from St
James' University Hospital, Leeds, believes this is due to low awareness of
what brachytherapy is and what types of cancers it helps treat.

"Brachytherapy is often used to treat prostate cancer,"
explains Dr Cooper, "but it is also a proven type of radiotherapy being used
successfully in a range of other cancers such as gynaecological, breast,
oesophagus, skin and rectal cancer."

The ICM survey confirmed that cancer patients frequently
access the Internet for treatment information.

"The more information available to patients and their
families, the better," added Matt Dawson. "Information about effective
treatment options like brachytherapy should be easy to find for anyone
dealing with cancer."

The 'Because Life is for Living' campaign and
www.aboutbrachytherapy.com website are supported by Nucletron.

Notes to editors

About Brachytherapy

Brachytherapy is a high-precision radiation therapy, in which the
radiation source used to kill cancer cells and shrink tumours is placed in or
close to the tumour itself. Brachytherapy offers a precise, highly effective
and well tolerated treatment option tailored to the needs of individual
patients. The precision brachytherapy approach allows a physician to
concentrate a high dose of radiation in a small area, minimising damage to
nearby, healthy body tissue and organs, over a shorter treatment period.

About the market research

The ICM Cancer Patient Survey was conducted in February 2010, based on a
pool of 598 online surveys completed by current or past cancer patients in
the UK, USA and Netherlands according to the following breakdown: 250 UK, 250
USA and 98 Netherlands respondents. Respondents were 54% male and 46% female
with ages varying from 18-65+ years old.

About Nucletron

Nucletron provides state of the art radiotherapy solutions for cancer
treatment that meet the evolving needs of patients, their carers and
healthcare professionals around the world. Nucletron has unmatched global
leadership in brachytherapy, a very precise, highly effective and
well-tolerated treatment option for healthcare providers, tailored to the
needs of individual patients. We work with clinical teams to constantly
improve and develop an innovative portfolio of integrated products, software
and services that assures excellent patient outcomes. Headquartered in
Veenendaal, The Netherlands, Nucletron employs more than 500 employees, with
offices in 15 countries, and products available in more than 100 countries
around the world. Please visit www.nucletron.com to learn more about
our healthcare solutions.

References:

1 Stewart AJ & Jones B. In Devlin Brachytherapy: Applications and
techniques. 2007.

2 Kupelian PA, Potters L, Khuntia D, et al. Int J Radiat Oncol Biol Phys
2004;58(1):25-33.

3 Pisansky TM, Gold DG, Furutani KM, et al. Mayo Clin Proc
2008;83(12):1364-72.

4 Dickler A, Patel RR, Wazer D. Expert Rev Med Devices 2009;6(3):325-33.

5 Viani GA, Manta GB, Stefano EJ, et al. J Exp Clin Cancer Res
2009;28:47.

For additional information or interviews with Matt Dawson, Prof Hoskin or
Dr Cooper please contact:

Danny Stepto, dstepto@rdcomms.com, Tel: +44(0)208-392-8042 or Ligia
Santos, lsantos@rdcomms.com, Tel: +44(0)208-392-6925 at Red Door
Communications

Dr Jonathan Briers, Vice President, Medical Affairs,
jonathan.briers@nl.nucletron.com, Tel: +31-318-557-231 at Nucletron

For additional information or interviews with Matt Dawson, Prof Hoskin or Dr Cooper please contact: Danny Stepto, dstepto at rdcomms.com, Tel: +44(0)208-392-8042 or Ligia Santos, lsantos at rdcomms.com, Tel: +44(0)208-392-6925 at Red Door Communications; Dr Jonathan Briers, Vice President, Medical Affairs, jonathan.briers at nl.nucletron.com, Tel: +31-318-557-231 at Nucletron